| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
WWL229 targets carboxylesterase 3 (Ces3), a serine hydrolase involved in lipolysis. Ces3 mediates triglyceride hydrolysis in adipose tissue, releasing free fatty acids into circulation. By selectively inhibiting Ces3 with an IC₅₀ of 1.94 µM, WWL229 reduces basal lipolysis and promotes lipid storage in adipocytes. It shows high selectivity over related enzymes.
|
|---|---|
| ln Vitro |
In vitro, WWL229 is a selective inhibitor of Ces3 with an IC₅₀ of 1.94 µM. It inhibits recombinant Ces3 while not affecting Ces1f, ABHD6, or other tested serine hydrolases, replicating the effects of WWL113 in adipocytes. It promotes lipid storage in cultured adipocytes and prevents basal lipolysis.
|
| ln Vivo |
In vivo activity data for WWL229 are limited in the available literature. As a research compound, its primary application is in in vitro studies of lipolysis and lipid metabolism. Its ability to promote lipid storage and prevent lipolysis suggests potential for studying obesity and metabolic disorders, but systematic in vivo studies are lacking.
|
| Enzyme Assay |
In vitro enzyme inhibition assays for WWL229 are performed using purified recombinant Ces3 enzyme. Enzyme activity is measured using fluorogenic or chromogenic ester substrates. The compound is incubated with the enzyme and substrate, and the inhibition of substrate hydrolysis is quantified. The IC₅₀ (1.94 µM) is calculated from concentration-response curves.
|
| Cell Assay |
In vitro cellular assays for WWL229 are performed using cultured adipocytes. Cells are treated with the compound, and lipid storage is measured by quantifying intracellular lipid accumulation (e.g., by Oil Red O staining). Basal lipolysis is assessed by measuring the release of free fatty acids or glycerol into the culture medium.
|
| Animal Protocol |
In vivo animal experiments for WWL229 are not extensively documented. As a research compound, in vivo studies would typically involve administration to animal models of obesity or metabolic disorders. The compound would be administered via appropriate routes, and efficacy would be assessed by measuring adipose tissue mass, circulating free fatty acids, and metabolic parameters.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of WWL229 have been characterized in part. The compound has a molecular weight of 322.36 and molecular formula C₁₆H₂₂N₂O₅. It is supplied as a research compound with purity ≥98%. Further PK details, including half-life, bioavailability, and tissue distribution, are available from the manufacturer's data sheets.
|
| Toxicity/Toxicokinetics |
Toxicological data for WWL229 are not extensively reported. As a research-use compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
WWL229 is a selective Ces3 inhibitor with an IC₅₀ of 1.94 µM. It promotes lipid storage in cultured adipocytes and prevents basal lipolysis. The compound is used in metabolic research to study lipolysis, lipid metabolism, and the role of carboxylesterases in adipose tissue function. This product is for research use only.
|
| Molecular Formula |
C16H22N2O5
|
|---|---|
| Molecular Weight |
322.356
|
| Exact Mass |
322.152
|
| Elemental Analysis |
C, 59.62; H, 6.88; N, 8.69; O, 24.82
|
| CAS # |
1338575-28-2
|
| PubChem CID |
72183487
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
449.1±41.0 °C at 760 mmHg
|
| Flash Point |
225.4±27.6 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.538
|
| LogP |
3.56
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
23
|
| Complexity |
390
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COCCCC1CCCCN1C(=O)OC2=CC=C(C=C2)[N+](=O)[O-]
|
| InChi Key |
XVBRVSAGMWRVCK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H22N2O5/c1-22-12-4-6-13-5-2-3-11-17(13)16(19)23-15-9-7-14(8-10-15)18(20)21/h7-10,13H,2-6,11-12H2,1H3
|
| Chemical Name |
(4-nitrophenyl) 2-(3-methoxypropyl)piperidine-1-carboxylate
|
| Synonyms |
WWL 229; WWL-229; WWL229
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~775.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1021 mL | 15.5106 mL | 31.0212 mL | |
| 5 mM | 0.6204 mL | 3.1021 mL | 6.2042 mL | |
| 10 mM | 0.3102 mL | 1.5511 mL | 3.1021 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
